Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brain Neoplasms | 52 | 2019 | 471 | 6.510 |
Why?
|
Glioma | 28 | 2018 | 114 | 4.020 |
Why?
|
Glioblastoma | 22 | 2019 | 125 | 3.670 |
Why?
|
Central Nervous System Neoplasms | 7 | 2014 | 24 | 2.400 |
Why?
|
Antineoplastic Agents | 17 | 2018 | 532 | 2.110 |
Why?
|
Antineoplastic Agents, Alkylating | 12 | 2019 | 32 | 1.940 |
Why?
|
Neoplasm Recurrence, Local | 16 | 2017 | 304 | 1.660 |
Why?
|
Dacarbazine | 11 | 2017 | 28 | 1.580 |
Why?
|
Radiotherapy | 12 | 2019 | 66 | 1.330 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2017 | 20 | 1.120 |
Why?
|
Middle Aged | 64 | 2019 | 10678 | 1.090 |
Why?
|
Neoplasms | 7 | 2018 | 596 | 1.060 |
Why?
|
Humans | 89 | 2019 | 28304 | 1.060 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2018 | 398 | 0.890 |
Why?
|
Adult | 53 | 2019 | 8243 | 0.870 |
Why?
|
Female | 63 | 2019 | 17679 | 0.830 |
Why?
|
Aged | 51 | 2019 | 9256 | 0.820 |
Why?
|
Treatment Outcome | 16 | 2019 | 2886 | 0.820 |
Why?
|
Male | 59 | 2019 | 16967 | 0.780 |
Why?
|
Meningioma | 4 | 2015 | 33 | 0.760 |
Why?
|
Combined Modality Therapy | 14 | 2018 | 498 | 0.720 |
Why?
|
Breast Neoplasms | 6 | 2019 | 655 | 0.710 |
Why?
|
Fatigue | 4 | 2015 | 68 | 0.690 |
Why?
|
Clinical Trials as Topic | 5 | 2018 | 293 | 0.680 |
Why?
|
Radiation Injuries | 3 | 2019 | 59 | 0.650 |
Why?
|
Taste Disorders | 3 | 2018 | 3 | 0.650 |
Why?
|
Olfaction Disorders | 3 | 2018 | 6 | 0.640 |
Why?
|
Hyperglycemia | 1 | 2017 | 82 | 0.620 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2016 | 91 | 0.580 |
Why?
|
Quality of Life | 11 | 2019 | 792 | 0.580 |
Why?
|
Endpoint Determination | 1 | 2016 | 18 | 0.570 |
Why?
|
Radiosurgery | 3 | 2014 | 221 | 0.570 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 20 | 0.550 |
Why?
|
Hemangiopericytoma | 2 | 2013 | 5 | 0.540 |
Why?
|
Aged, 80 and over | 25 | 2019 | 3562 | 0.540 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2015 | 101 | 0.530 |
Why?
|
Follow-Up Studies | 17 | 2018 | 2027 | 0.530 |
Why?
|
Astrocytoma | 3 | 2018 | 25 | 0.510 |
Why?
|
Dapsone | 1 | 2014 | 3 | 0.500 |
Why?
|
Anemia, Hemolytic | 1 | 2014 | 6 | 0.500 |
Why?
|
Hydroxamic Acids | 1 | 2014 | 17 | 0.490 |
Why?
|
Procarbazine | 2 | 2011 | 4 | 0.490 |
Why?
|
Lymphoma | 2 | 2011 | 35 | 0.490 |
Why?
|
Thalidomide | 2 | 2011 | 28 | 0.480 |
Why?
|
Taste | 1 | 2013 | 11 | 0.480 |
Why?
|
Ubiquinone | 1 | 2013 | 9 | 0.460 |
Why?
|
Hematologic Diseases | 1 | 2013 | 23 | 0.460 |
Why?
|
Influenza Vaccines | 1 | 2014 | 70 | 0.460 |
Why?
|
Semen | 1 | 2013 | 9 | 0.460 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2012 | 6 | 0.460 |
Why?
|
Sperm Motility | 1 | 2013 | 8 | 0.460 |
Why?
|
Smell | 1 | 2013 | 42 | 0.460 |
Why?
|
Vitamins | 1 | 2013 | 56 | 0.440 |
Why?
|
Angiogenesis Inhibitors | 2 | 2014 | 33 | 0.440 |
Why?
|
Venous Thromboembolism | 1 | 2012 | 25 | 0.440 |
Why?
|
Melanoma | 1 | 2013 | 137 | 0.430 |
Why?
|
Protein Kinase Inhibitors | 2 | 2013 | 73 | 0.430 |
Why?
|
Pulmonary Embolism | 1 | 2012 | 46 | 0.430 |
Why?
|
Nitrogen Mustard Compounds | 1 | 2012 | 3 | 0.430 |
Why?
|
Prognosis | 12 | 2018 | 1342 | 0.420 |
Why?
|
Medication Adherence | 1 | 2013 | 146 | 0.400 |
Why?
|
Young Adult | 16 | 2018 | 2321 | 0.400 |
Why?
|
Pain | 2 | 2019 | 247 | 0.350 |
Why?
|
DNA Methylation | 5 | 2018 | 125 | 0.350 |
Why?
|
DNA Modification Methylases | 4 | 2018 | 9 | 0.340 |
Why?
|
DNA Repair Enzymes | 4 | 2018 | 14 | 0.340 |
Why?
|
Anticoagulants | 2 | 2012 | 119 | 0.340 |
Why?
|
Pilot Projects | 4 | 2015 | 437 | 0.330 |
Why?
|
Disease-Free Survival | 9 | 2019 | 265 | 0.330 |
Why?
|
Tumor Suppressor Proteins | 4 | 2018 | 72 | 0.330 |
Why?
|
Meningeal Neoplasms | 3 | 2014 | 30 | 0.310 |
Why?
|
Administration, Oral | 5 | 2017 | 163 | 0.300 |
Why?
|
Saliva | 2 | 2018 | 31 | 0.290 |
Why?
|
Cognition Disorders | 3 | 2015 | 388 | 0.290 |
Why?
|
Dietary Supplements | 3 | 2018 | 171 | 0.290 |
Why?
|
Survival Rate | 10 | 2019 | 775 | 0.280 |
Why?
|
Magnetic Resonance Imaging | 7 | 2017 | 1144 | 0.280 |
Why?
|
Esthesioneuroblastoma, Olfactory | 1 | 2005 | 2 | 0.280 |
Why?
|
Double-Blind Method | 7 | 2019 | 480 | 0.280 |
Why?
|
Nasal Cavity | 1 | 2005 | 5 | 0.280 |
Why?
|
Nose Neoplasms | 1 | 2005 | 4 | 0.280 |
Why?
|
Prospective Studies | 7 | 2019 | 1932 | 0.270 |
Why?
|
Thromboembolism | 1 | 2004 | 29 | 0.260 |
Why?
|
Neoplasm Staging | 5 | 2018 | 430 | 0.250 |
Why?
|
Plant Extracts | 2 | 2017 | 59 | 0.250 |
Why?
|
Spinal Cord Compression | 1 | 2003 | 5 | 0.240 |
Why?
|
Maximum Tolerated Dose | 8 | 2018 | 55 | 0.240 |
Why?
|
Spinal Neoplasms | 1 | 2003 | 17 | 0.240 |
Why?
|
Hospice Care | 1 | 2003 | 11 | 0.240 |
Why?
|
Genomics | 3 | 2018 | 78 | 0.230 |
Why?
|
Anticonvulsants | 6 | 2010 | 51 | 0.230 |
Why?
|
Home Care Services | 1 | 2003 | 39 | 0.230 |
Why?
|
Health Services Needs and Demand | 1 | 2003 | 66 | 0.230 |
Why?
|
Neuropsychological Tests | 3 | 2019 | 370 | 0.220 |
Why?
|
Retrospective Studies | 7 | 2018 | 2930 | 0.210 |
Why?
|
Salivary Proteins and Peptides | 2 | 2018 | 2 | 0.200 |
Why?
|
Camptothecin | 3 | 2008 | 48 | 0.200 |
Why?
|
Electromagnetic Fields | 2 | 2018 | 25 | 0.200 |
Why?
|
Salvage Therapy | 4 | 2015 | 91 | 0.200 |
Why?
|
Lung Neoplasms | 2 | 2016 | 374 | 0.200 |
Why?
|
Time Factors | 7 | 2017 | 1874 | 0.190 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2014 | 35 | 0.190 |
Why?
|
Brain | 3 | 2017 | 809 | 0.190 |
Why?
|
Disease Management | 2 | 2018 | 105 | 0.190 |
Why?
|
Promoter Regions, Genetic | 2 | 2018 | 218 | 0.190 |
Why?
|
Vena Cava Filters | 2 | 2012 | 14 | 0.180 |
Why?
|
Cancer Vaccines | 1 | 2019 | 21 | 0.180 |
Why?
|
Indans | 2 | 2018 | 21 | 0.180 |
Why?
|
Disease Susceptibility | 1 | 2019 | 53 | 0.170 |
Why?
|
Dendritic Cells | 1 | 2019 | 61 | 0.170 |
Why?
|
Lactoferrin | 1 | 2018 | 2 | 0.170 |
Why?
|
Postoperative Complications | 2 | 2014 | 634 | 0.170 |
Why?
|
Radiodermatitis | 1 | 2018 | 5 | 0.170 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 38 | 0.160 |
Why?
|
Genetic Predisposition to Disease | 2 | 2019 | 938 | 0.160 |
Why?
|
Etoposide | 1 | 2017 | 29 | 0.160 |
Why?
|
Vincristine | 1 | 2017 | 14 | 0.160 |
Why?
|
Cyclophosphamide | 1 | 2017 | 25 | 0.160 |
Why?
|
Karnofsky Performance Status | 3 | 2014 | 7 | 0.160 |
Why?
|
Prednisone | 1 | 2017 | 43 | 0.160 |
Why?
|
Neuronavigation | 1 | 2017 | 5 | 0.160 |
Why?
|
Cohort Studies | 7 | 2019 | 1673 | 0.160 |
Why?
|
Survivors | 2 | 2018 | 141 | 0.160 |
Why?
|
Electroporation | 1 | 2017 | 14 | 0.160 |
Why?
|
Doxorubicin | 1 | 2017 | 55 | 0.160 |
Why?
|
Tumor Burden | 1 | 2017 | 55 | 0.160 |
Why?
|
Ablation Techniques | 1 | 2017 | 20 | 0.160 |
Why?
|
Ephrin-A1 | 1 | 2017 | 11 | 0.160 |
Why?
|
Receptors, Somatostatin | 2 | 2014 | 5 | 0.160 |
Why?
|
Craniotomy | 1 | 2017 | 26 | 0.160 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2017 | 4 | 0.150 |
Why?
|
Calcium Channels, T-Type | 1 | 2017 | 18 | 0.150 |
Why?
|
Cardiac Volume | 1 | 2017 | 11 | 0.150 |
Why?
|
C-Reactive Protein | 1 | 2018 | 236 | 0.150 |
Why?
|
Hypoglycemic Agents | 1 | 2018 | 177 | 0.150 |
Why?
|
Neoplastic Stem Cells | 1 | 2018 | 88 | 0.150 |
Why?
|
Quinazolines | 1 | 2017 | 30 | 0.150 |
Why?
|
Piperazines | 1 | 2017 | 41 | 0.150 |
Why?
|
Surgery, Computer-Assisted | 1 | 2017 | 50 | 0.150 |
Why?
|
Micronutrients | 1 | 2017 | 15 | 0.150 |
Why?
|
Dideoxynucleosides | 1 | 2016 | 1 | 0.150 |
Why?
|
Genome, Human | 1 | 2017 | 148 | 0.150 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2016 | 63 | 0.150 |
Why?
|
Phytotherapy | 2 | 2017 | 38 | 0.150 |
Why?
|
Neoplasm Proteins | 1 | 2017 | 143 | 0.140 |
Why?
|
Biopsy | 1 | 2017 | 240 | 0.140 |
Why?
|
Heart Ventricles | 1 | 2017 | 115 | 0.140 |
Why?
|
Central Nervous System | 1 | 2016 | 23 | 0.140 |
Why?
|
Cranial Irradiation | 2 | 2014 | 69 | 0.140 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2017 | 145 | 0.140 |
Why?
|
Positron-Emission Tomography | 1 | 2016 | 134 | 0.140 |
Why?
|
Head | 1 | 2016 | 46 | 0.140 |
Why?
|
Ventricular Function, Left | 1 | 2017 | 201 | 0.140 |
Why?
|
Survival Analysis | 4 | 2011 | 424 | 0.140 |
Why?
|
Benzhydryl Compounds | 1 | 2015 | 7 | 0.130 |
Why?
|
Mutation | 2 | 2017 | 451 | 0.130 |
Why?
|
Ganglioglioma | 1 | 2015 | 4 | 0.130 |
Why?
|
Cholinesterase Inhibitors | 1 | 2015 | 28 | 0.130 |
Why?
|
Radiotherapy Dosage | 2 | 2013 | 86 | 0.130 |
Why?
|
Head and Neck Neoplasms | 1 | 2017 | 116 | 0.130 |
Why?
|
Somatostatin | 1 | 2014 | 9 | 0.130 |
Why?
|
Blood Glucose | 1 | 2017 | 485 | 0.130 |
Why?
|
Radiotherapy, Intensity-Modulated | 2 | 2014 | 27 | 0.130 |
Why?
|
Inflammation | 1 | 2018 | 501 | 0.130 |
Why?
|
Piperidines | 1 | 2015 | 84 | 0.130 |
Why?
|
Meningeal Carcinomatosis | 1 | 2014 | 4 | 0.130 |
Why?
|
Indoles | 1 | 2014 | 51 | 0.130 |
Why?
|
Stroke Volume | 1 | 2017 | 278 | 0.130 |
Why?
|
Influenza B virus | 1 | 2014 | 15 | 0.120 |
Why?
|
Influenza A Virus, H3N2 Subtype | 1 | 2014 | 17 | 0.120 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2013 | 5 | 0.120 |
Why?
|
Body Composition | 1 | 2016 | 365 | 0.120 |
Why?
|
Cyclohexanols | 1 | 2013 | 11 | 0.120 |
Why?
|
Epidermal Cyst | 1 | 2013 | 4 | 0.120 |
Why?
|
Androgen Antagonists | 1 | 2013 | 15 | 0.120 |
Why?
|
Spinal Cord Neoplasms | 1 | 2013 | 9 | 0.120 |
Why?
|
Receptor, erbB-2 | 1 | 2013 | 44 | 0.120 |
Why?
|
Serotonin Uptake Inhibitors | 1 | 2013 | 31 | 0.120 |
Why?
|
Blood Cell Count | 1 | 2013 | 26 | 0.120 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2013 | 56 | 0.120 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2004 | 47 | 0.120 |
Why?
|
Soybean Proteins | 1 | 2013 | 64 | 0.120 |
Why?
|
Hot Flashes | 1 | 2013 | 46 | 0.120 |
Why?
|
Up-Regulation | 1 | 2013 | 180 | 0.120 |
Why?
|
Dose-Response Relationship, Drug | 6 | 2013 | 436 | 0.120 |
Why?
|
Self Administration | 1 | 2013 | 66 | 0.120 |
Why?
|
Pipecolic Acids | 1 | 2012 | 6 | 0.110 |
Why?
|
Hirudins | 1 | 2012 | 19 | 0.110 |
Why?
|
Polysaccharides | 1 | 2012 | 13 | 0.110 |
Why?
|
Thrombocytopenia | 1 | 2012 | 31 | 0.110 |
Why?
|
Gonadal Steroid Hormones | 1 | 2013 | 28 | 0.110 |
Why?
|
Warfarin | 1 | 2012 | 30 | 0.110 |
Why?
|
Neoplasm Metastasis | 3 | 2013 | 192 | 0.110 |
Why?
|
Software | 1 | 2013 | 106 | 0.110 |
Why?
|
Venous Thrombosis | 1 | 2012 | 48 | 0.110 |
Why?
|
Snake Venoms | 1 | 2012 | 2 | 0.110 |
Why?
|
Ginkgo biloba | 1 | 2012 | 19 | 0.110 |
Why?
|
Mood Disorders | 1 | 2012 | 19 | 0.110 |
Why?
|
Patient Participation | 1 | 2013 | 60 | 0.110 |
Why?
|
Plant Preparations | 1 | 2012 | 21 | 0.110 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2013 | 139 | 0.110 |
Why?
|
Recombinant Proteins | 1 | 2012 | 240 | 0.110 |
Why?
|
Panax | 1 | 2012 | 8 | 0.110 |
Why?
|
Hemorrhage | 1 | 2012 | 86 | 0.110 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2012 | 17 | 0.110 |
Why?
|
Respiratory Tract Infections | 1 | 2012 | 40 | 0.100 |
Why?
|
Magnetic Resonance Angiography | 1 | 2011 | 59 | 0.100 |
Why?
|
Adolescent | 5 | 2018 | 3184 | 0.100 |
Why?
|
Skin Neoplasms | 1 | 2013 | 205 | 0.100 |
Why?
|
Mental Status Schedule | 1 | 2011 | 24 | 0.100 |
Why?
|
Immunosuppression | 1 | 2011 | 80 | 0.100 |
Why?
|
Medulloblastoma | 1 | 2010 | 6 | 0.100 |
Why?
|
Cerebellar Neoplasms | 1 | 2010 | 8 | 0.100 |
Why?
|
Poly I-C | 1 | 2010 | 4 | 0.100 |
Why?
|
Interferon Inducers | 1 | 2010 | 2 | 0.100 |
Why?
|
Polylysine | 1 | 2010 | 5 | 0.100 |
Why?
|
Epothilones | 1 | 2010 | 3 | 0.100 |
Why?
|
Radiation Oncology | 1 | 2010 | 8 | 0.100 |
Why?
|
Boronic Acids | 1 | 2010 | 7 | 0.090 |
Why?
|
Pyrazines | 1 | 2010 | 11 | 0.090 |
Why?
|
Disease Progression | 4 | 2018 | 566 | 0.090 |
Why?
|
Odds Ratio | 1 | 2011 | 457 | 0.090 |
Why?
|
Quinolones | 1 | 2008 | 4 | 0.080 |
Why?
|
Prostatic Neoplasms | 1 | 2013 | 438 | 0.080 |
Why?
|
Cognition | 2 | 2015 | 512 | 0.080 |
Why?
|
Pyrrolidines | 1 | 2008 | 9 | 0.080 |
Why?
|
Medical Oncology | 1 | 2009 | 70 | 0.080 |
Why?
|
Chromosome Mapping | 1 | 2009 | 213 | 0.080 |
Why?
|
Reproducibility of Results | 3 | 2016 | 700 | 0.080 |
Why?
|
Phenytoin | 1 | 2008 | 4 | 0.080 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2010 | 441 | 0.080 |
Why?
|
Pyrazoles | 1 | 2008 | 51 | 0.080 |
Why?
|
Methylphenidate | 1 | 2007 | 10 | 0.080 |
Why?
|
Sulfonamides | 1 | 2008 | 67 | 0.080 |
Why?
|
Central Nervous System Stimulants | 1 | 2007 | 28 | 0.080 |
Why?
|
Radiotherapy, Conformal | 2 | 2018 | 19 | 0.080 |
Why?
|
Antioxidants | 2 | 2018 | 117 | 0.070 |
Why?
|
Stereotaxic Techniques | 1 | 2006 | 15 | 0.070 |
Why?
|
Immunotherapy | 2 | 2018 | 65 | 0.070 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2018 | 247 | 0.070 |
Why?
|
Feasibility Studies | 2 | 2018 | 247 | 0.070 |
Why?
|
Cell Line, Tumor | 2 | 2018 | 659 | 0.070 |
Why?
|
Cell Proliferation | 2 | 2018 | 567 | 0.070 |
Why?
|
Dalteparin | 1 | 2004 | 1 | 0.070 |
Why?
|
Supratentorial Neoplasms | 1 | 2004 | 2 | 0.060 |
Why?
|
Enoxaparin | 1 | 2004 | 19 | 0.060 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2015 | 66 | 0.060 |
Why?
|
Oxidative Stress | 2 | 2018 | 249 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 3 | 2016 | 858 | 0.060 |
Why?
|
Heparin | 1 | 2004 | 73 | 0.060 |
Why?
|
Observer Variation | 2 | 2016 | 96 | 0.060 |
Why?
|
Methotrexate | 1 | 2004 | 60 | 0.060 |
Why?
|
Suramin | 1 | 2004 | 1 | 0.060 |
Why?
|
Laminectomy | 1 | 2003 | 10 | 0.060 |
Why?
|
Nursing Assessment | 1 | 2003 | 10 | 0.060 |
Why?
|
Dexamethasone | 1 | 2003 | 39 | 0.060 |
Why?
|
Embolization, Therapeutic | 1 | 2003 | 42 | 0.060 |
Why?
|
Decompression, Surgical | 1 | 2003 | 43 | 0.060 |
Why?
|
Focus Groups | 1 | 2003 | 97 | 0.060 |
Why?
|
Sensitivity and Specificity | 2 | 2016 | 521 | 0.060 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2015 | 162 | 0.060 |
Why?
|
Animals | 3 | 2018 | 6402 | 0.050 |
Why?
|
Life Style | 1 | 2004 | 372 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2018 | 846 | 0.050 |
Why?
|
Diet | 1 | 2004 | 346 | 0.050 |
Why?
|
Cytarabine | 1 | 2002 | 52 | 0.050 |
Why?
|
Pain Measurement | 1 | 2003 | 328 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2004 | 369 | 0.050 |
Why?
|
Child | 2 | 2017 | 2151 | 0.050 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2003 | 317 | 0.050 |
Why?
|
Multidrug Resistance-Associated Proteins | 1 | 2019 | 3 | 0.050 |
Why?
|
Calcium-Binding Proteins | 1 | 2019 | 46 | 0.040 |
Why?
|
Antigens, Neoplasm | 1 | 2019 | 44 | 0.040 |
Why?
|
Cell Adhesion Molecules | 1 | 2019 | 44 | 0.040 |
Why?
|
Analysis of Variance | 2 | 2012 | 390 | 0.040 |
Why?
|
Immunity, Mucosal | 1 | 2018 | 5 | 0.040 |
Why?
|
Minerals | 1 | 2018 | 10 | 0.040 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 2018 | 3 | 0.040 |
Why?
|
Sulfones | 1 | 2018 | 12 | 0.040 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2018 | 12 | 0.040 |
Why?
|
Lymphatic Metastasis | 1 | 2018 | 156 | 0.040 |
Why?
|
Drug Interactions | 2 | 2008 | 55 | 0.040 |
Why?
|
RNA Interference | 1 | 2018 | 71 | 0.040 |
Why?
|
Transcriptional Activation | 1 | 2018 | 40 | 0.040 |
Why?
|
RNA, Small Interfering | 1 | 2018 | 102 | 0.040 |
Why?
|
Neoplasm Transplantation | 1 | 2018 | 75 | 0.040 |
Why?
|
Proteomics | 1 | 2018 | 86 | 0.040 |
Why?
|
Genetic Testing | 1 | 2018 | 93 | 0.040 |
Why?
|
Transplantation, Heterologous | 1 | 2018 | 120 | 0.040 |
Why?
|
Iron | 1 | 2018 | 114 | 0.040 |
Why?
|
Mibefradil | 1 | 2017 | 1 | 0.040 |
Why?
|
Cell Size | 1 | 2017 | 27 | 0.040 |
Why?
|
Receptor, EphA2 | 1 | 2017 | 11 | 0.040 |
Why?
|
DNA Repair | 1 | 2017 | 50 | 0.040 |
Why?
|
Cell Death | 1 | 2017 | 66 | 0.040 |
Why?
|
Membrane Potentials | 1 | 2017 | 63 | 0.040 |
Why?
|
Astrocytes | 1 | 2017 | 45 | 0.040 |
Why?
|
Coculture Techniques | 1 | 2017 | 74 | 0.040 |
Why?
|
Powders | 1 | 2017 | 7 | 0.040 |
Why?
|
Mice, Nude | 1 | 2018 | 271 | 0.040 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 2017 | 13 | 0.040 |
Why?
|
Tissue Distribution | 1 | 2017 | 50 | 0.040 |
Why?
|
Cell Movement | 1 | 2018 | 157 | 0.040 |
Why?
|
Ki-67 Antigen | 1 | 2017 | 29 | 0.040 |
Why?
|
Diastole | 1 | 2017 | 96 | 0.040 |
Why?
|
Finite Element Analysis | 1 | 2017 | 80 | 0.040 |
Why?
|
Risk Factors | 2 | 2015 | 3520 | 0.040 |
Why?
|
Magnetic Resonance Imaging, Cine | 1 | 2017 | 64 | 0.040 |
Why?
|
Hydrogels | 1 | 2017 | 100 | 0.040 |
Why?
|
Genome-Wide Association Study | 1 | 2019 | 615 | 0.040 |
Why?
|
Skin | 1 | 2018 | 200 | 0.040 |
Why?
|
Radiopharmaceuticals | 1 | 2016 | 84 | 0.040 |
Why?
|
Collagen | 1 | 2017 | 221 | 0.040 |
Why?
|
Radiography, Abdominal | 1 | 2016 | 16 | 0.040 |
Why?
|
Area Under Curve | 2 | 2008 | 77 | 0.030 |
Why?
|
Abdominal Fat | 1 | 2016 | 46 | 0.030 |
Why?
|
Ethnic Groups | 1 | 2018 | 450 | 0.030 |
Why?
|
Signal Transduction | 1 | 2019 | 607 | 0.030 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2016 | 111 | 0.030 |
Why?
|
Neovascularization, Pathologic | 1 | 2016 | 82 | 0.030 |
Why?
|
Affect | 1 | 2015 | 53 | 0.030 |
Why?
|
Models, Biological | 1 | 2017 | 356 | 0.030 |
Why?
|
Age Factors | 1 | 2018 | 1058 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2014 | 18 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2006 | 221 | 0.030 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2014 | 74 | 0.030 |
Why?
|
Infant | 1 | 2017 | 928 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2019 | 1236 | 0.030 |
Why?
|
Child, Preschool | 1 | 2017 | 1126 | 0.030 |
Why?
|
Treatment Failure | 1 | 2014 | 142 | 0.030 |
Why?
|
Confidence Intervals | 2 | 2004 | 136 | 0.030 |
Why?
|
Memory | 1 | 2015 | 175 | 0.030 |
Why?
|
Rats | 1 | 2017 | 1425 | 0.030 |
Why?
|
MutS Homolog 2 Protein | 1 | 2013 | 4 | 0.030 |
Why?
|
Thoracic Vertebrae | 1 | 2013 | 41 | 0.030 |
Why?
|
Immunoenzyme Techniques | 1 | 2013 | 45 | 0.030 |
Why?
|
Research Design | 1 | 2015 | 271 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2013 | 69 | 0.030 |
Why?
|
Nuclear Proteins | 1 | 2013 | 71 | 0.030 |
Why?
|
Adipose Tissue | 1 | 2016 | 337 | 0.030 |
Why?
|
Mice | 1 | 2018 | 2181 | 0.030 |
Why?
|
Integrins | 1 | 2012 | 18 | 0.030 |
Why?
|
Prevalence | 1 | 2014 | 881 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2014 | 886 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 1 | 2011 | 31 | 0.030 |
Why?
|
Acute Disease | 1 | 2012 | 234 | 0.030 |
Why?
|
Otitis Media | 1 | 2011 | 19 | 0.020 |
Why?
|
Craniopharyngioma | 1 | 2010 | 4 | 0.020 |
Why?
|
Pituitary Neoplasms | 1 | 2010 | 11 | 0.020 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2010 | 35 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 2010 | 31 | 0.020 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2010 | 18 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2011 | 631 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2012 | 283 | 0.020 |
Why?
|
Neoplasm, Residual | 1 | 2008 | 23 | 0.020 |
Why?
|
Incidence | 1 | 2012 | 1087 | 0.020 |
Why?
|
Hospitalization | 1 | 2011 | 386 | 0.020 |
Why?
|
Neurosurgical Procedures | 1 | 2008 | 52 | 0.020 |
Why?
|
United States | 1 | 2016 | 3588 | 0.020 |
Why?
|
Least-Squares Analysis | 1 | 2007 | 29 | 0.020 |
Why?
|
Seizures | 1 | 2008 | 47 | 0.020 |
Why?
|
Patient Dropouts | 1 | 2007 | 23 | 0.020 |
Why?
|
Enzyme Induction | 1 | 2006 | 31 | 0.020 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 1 | 2006 | 33 | 0.020 |
Why?
|
Remission Induction | 1 | 2004 | 76 | 0.020 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2003 | 38 | 0.010 |
Why?
|
Recurrence | 1 | 2003 | 210 | 0.010 |
Why?
|
Delayed-Action Preparations | 1 | 2002 | 34 | 0.010 |
Why?
|
Injections, Spinal | 1 | 2002 | 108 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2004 | 706 | 0.010 |
Why?
|